BlackRock holds a 7.6% stake in Altimmune, Inc. as of August 13, 2025.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BlackRock holds a 7.6% stake in Altimmune, Inc. as of August 13, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
BlackRock
American multinational investment management corporation
-
Altimmune, Inc.
American biopharmaceutical company
Related events
- Citigroup provided a stock rating for Altimmune, Inc.
- BlackRock is the largest shareholder in a company involving Axos Financial as of August 2, 2025.
- Institutional investors Vanguard, BlackRock, and State Street reported their ownership stakes in a company on July 19, 2025.
- Access Industries is the largest shareholder in a company, followed by BlackRock and The Vanguard Group as significant shareholders.
- BlackRock increased its holdings in D-Wave Quantum Inc.
Coverage
Newest first; wire copies grouped- Simply Wall St.Individual investors account for 51% of Altimmune, Inc.'s (NASDAQ:ALT) ownership, while institutions account for 48% Explore Altimmune's Fair Values from the Community and select yours The considera